Toni joins the Scientific Advisory Board of Argonaute RNA Ltd

We are delighted to announce that Prof. Antonio Vidal-Puig has accepted an appointment to the Scientific Advisory Board of Argonaute RNA Ltd, a pioneering biotech company based in Cardiff, Wales, focused on next-generation RNA interference (RNAi) therapies for cardiometabolic and other high-unmet-need diseases.

Argonaute RNA is developing innovative gene-silencing therapeutics based on two proprietary platforms:

• PULSE siRNA™: A stabilised small interfering RNA (siRNA) platform designed for acute indications where a short duration of target gene knock-down is critical. The company emphasises “ideal peak knock-down → rapid recovery” profiles enabled without heavy chemical modification.

• Argo Dual siRNA: A bispecific siRNA chemistry combining two gene-silencing agents into a single molecule, aimed at complex, multi-factorial diseases (e.g., cardiometabolic disorders) where silencing a single gene may not suffice. The platform leverages DNA-nanotechnology style design and manufacturing cost-advantages.

Argonaute RNA’s broader mission is to harness RNAi, a cell-mechanism that inhibits the expression of specific genes, thereby modulating protein production and disease pathways. Their proprietary method of siRNA stabilisation helps overcome historic obstacles in siRNA drug development for human use.